- Cryptococcal and Candida endocarditis (in addition to amphotericin B).
- Cryptococcal meningitis (in addition to amphotericin B).
- Cryptococcal and Candida pneumonia (in addition to amphotericin B).
- Cryptococcal and Candida septicemia (in addition to amphotericin B).
- Cryptococcal and Candida urinary tract infections (in addition to amphotericin B).
250 mg 100/caps
500 mg 100/caps
*Prices represent cost per unit specified, are representative of "Average Wholesale Price" (AWP).
^Dosage is indicated in mg unless otherwise noted.
USUAL ADULT DOSING
- 25 mg/kg PO q6h in combination with amphotericin B products
- Sole exception: Monotherapy can be used for Candida UTI, e.g. azole-resistant candiduria.
- Obesity: Use IBW for dosing.
- Therapeutic drug monitoring recommended with renal insufficiency.
- Goal peak, 2 hrs post-dose after 3-5 days: 30-80 mcg/mL
ADULT RENAL DOSING
DOSING FOR GLOMERULAR FILTRATION OF 50-80
25 mg/kg q6h.
DOSING FOR GLOMERULAR FILTRATION OF 10-50
25 mg/kg q12-24h (monitor CBC and serum levels with appropriate dose adjustments).
DOSING FOR GLOMERULAR FILTRATION OF <10 ML/MIN
25 mg/kg q24-48h (monitor CBC serum levels closely with appropriate dose adjustments).
DOSING IN HEMODIALYSIS
25 mg/kg q24-48h. Dose post-dialysis on days of dialysis (monitor CBC and serum levels w/ appropriate dose adjustment).
DOSING IN PERITONEAL DIALYSIS
0.5-1.0 gm q24h (monitor CBC and serum levels w/ appropriate dose adjustments).
DOSING IN HEMOFILTRATION
CVVH and CVVHD: no data. Consider 25 mg/kg q24 for dialysis rate of 1L/hr and 25 mg/kg q12h for dialysis rate > or = 1.5 L/hr (monitor CBC and serum levels with appropriate dose adjustments).
USUAL PEDIATRIC DOSING
- 25 mg/kg PO q6h
- Adjust dose to maintain flucytosine concentrations (2-hour post-dose) between 40-60 mcg/mL.
- Obtain drug levels after 3-54 days of continuous dosing.
PEDIATRIC RENAL DOSING
- 20-40 mL/min: 25 mg/kg q12h
- 10-20 mL/min: 25mg/kg q24 h
- < 10 ml/min: 25mg/kg q24-48h
- Important to adjust dose to maintain 2-hour post-dose between 40-60 mcg/mL.
- Supplemental dose needed after hemodialysis or peritoneal dialysis.
Pediatric Dosing Author: George K Siberry, MD, MPH
ADVERSE DRUG REACTIONS
- GI intolerance: diarrhea, dyspepsia, and abdominal pain
- Marrow suppression: leukopenia or thrombocytopenia (with concentrations >100 mcg/mL)
- Taste perversion
- Hepatitis (hepatic necrosis has been reported)
- Peripheral neuropathy
- Fatal bone marrow aplasia
Flucytosine interferes with protein synthesis by incorporation into fungal RNA after being converted to 5-FU intracellularly.
Metabolism and Excretion
Minimal metabolism; principally excreted unchanged in the urine. Unabsorbed drug excreted in feces.
Cmax, Cmin, and AUC
30-40 mcg/mL after 2 g PO
Widely distributed into body tissues and fluids such as liver, kidney, spleen, heart, aqueous humor and bronchial secretion. Good CNS penetration (60-100% of serum concentration attained in the CSF).
DOSING FOR DECREASED HEPATIC FUNCTION
No data. Usual dose likely.
Category C: Teratogenicity reported in animal studies. Partially metabolized to 5-fluorouracil, a known human teratogen. Avoid use in first trimester.
BREAST FEEDING COMPATIBILITY
No data. Breast feeding during flucytosine therapy not recommended because of concern for potential adverse effects.
- Another old, generic drug that has become quite costly and may run upwards of $750.00-$1,000.00 (+) per day depending on weight of patient.
- Most often used as part of recommended combination with amphotericin for treatment of cryptococcal meningitis, resulting in more rapid CSF sterilization, but clinical outcome similar with or without flucytosine.
- Should be used if tolerated, but can treat with amphotericin B alone if toxicity develops.
- Close monitoring of renal function and serum level critical to prevent bone marrow suppression.
- 5-FC may be considered in combination with amphotericin (and surgery) in the treatment of candidal endocarditis.
- Flucytosine should never be used alone due to the rapid development of resistance, with the exception of candiduria.
- Yao ZW et al: Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis Feb 20 [PMID:24550039]
Comment: Group exmained primary outcomes using mortality d14 and d70 with secondary outcome as early fungicidal activity (EFA) at 2 weeks. Four trials were identified. Meta-analysis found lower mortality in patients given AmB + 5-FC at the 2 weeks point--combination group 44% [risk ratio (RR) 0.56, 95% confidence interval (CI) 0.33-0.95, p = 0.03]. EFA was significantly shorter in patients receiving AmB plus 5-FC [mean difference (MD) -0.10 log10 colony-forming units (CFU) per day, 95 % CI -0.11-0.09, p < 0.00001]. Mortality was no different between the 5-FC and fluconazole groups at the 3 months time point (p = 0.15) Adverse events occurred with similar frequency between the two treatment groups. There was no statistically significant difference in the survival rate between AmB in combination with high-dose fluconazole and the current standard of AmB plus 5-FC therapy for HIV-associated cryptococcal meningitis.
- Perfect JR et al: Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 50:291, 2010 [PMID:20047480]
Comment: Flucytosine plus AmphoB, liposomal AmB, or AmB lipid complex (for a minimum of 2 weeks) is recommended for the treatment of cryptococcal meningoencephalitis. Without flucytosine, the recommended amphoB treatment duration is 4-6 weeks. Fluconazole 1200 mg/day plus flucytosine x 6 weeks can be considered as an alternative in patients unable to tolerate amphoB.
- Vermes A, Guchelaar HJ, Dankert J: Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 46:171, 2000 [PMID:10933638]
Comment: Focused review on pharmacological aspects of this antifungal drug, originally developed in 1957 as an antimetabolite
- Saag MS et al: A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 28:291, 1999 [PMID:10064246]
Comment: Fluconazole superior to itraconazole for maintenance therapy of cryptococcal meningitis. Factor best associated with relapse was having not received flucytosine during the initial 2 wks of primary treatment for cryptococcal disease (relative risk = 5.88; 95% confidence interval, 1.27-27.14; p=0.04).
- van der Horst CM et al: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 337:15, 1997 [PMID:9203426]
Comment: Addition of 5FC to amphotericin resulted in faster CSF sterilization but did not improve clinical outcome.
Johns Hopkins Guides provide diagnosis, management, and treatment guidance for infectious diseases, diabetes, and psychiatric conditions. Learn more.